Skip to main content

FDA Bans Sale Of Juul's Vaping Products

FDA Bans Sale Of Juul's Vaping Products

FDA Bans Sale Of Juul's Vaping Products

Introduction

U.S. Food and Drug Administration has rejected the authorization of JUUL vaping products' sale by banning the products from the U.S. market, citing the long-term effects of teen vaping addiction.

JUUL introduced the vape pens of various flavors in 2015, which made the products popular in no time among the teens throughout the U.S. The USB-like design of the vape pens allowed the teens to hide them from parents and school officials, which resulted in growing teen addiction.

JUUL marketed the products extensively through social media and other mediums, targeting the prior non-smokers and minors. This led to an increased rate of nicotine addiction among teens throughout the nation, eventually resulting in a ban on the products.

The company denied all the allegations and disagreed with the findings of the F.D.A. The spokesperson for the JUUL said that the company is looking forward to appealing the decision of the product ban.

Currently, the company faces hundreds of lawsuits from families of teens and young adults against vape products. The lawsuits allege that the manufacturer specifically designed the products to lure the children to use the e-cigarettes resulting in lifetime addiction for them. The lawsuits even allege that JUUL failed to warn about nicotine concentrations and potentially harmful chemicals in the vape pens.

There are four types of JUULpods and a JUUL device. The pods manufactured by JUUL include Virginia tobacco-flavored pods and menthol-flavored pods with 5.0% and 3.0% nicotine concentrations.

According to a federal survey, the use of e-cigarettes among teens increased in 2017 and 2018 due to the rise in the popularity of vape products. The usage rate of the products among high school students was 11.7% in 2017, which rose to 27.5% in 2019 and drastically decreased to 11.3% in 2021.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!